JP2017515812A5 - - Google Patents

Download PDF

Info

Publication number
JP2017515812A5
JP2017515812A5 JP2016565334A JP2016565334A JP2017515812A5 JP 2017515812 A5 JP2017515812 A5 JP 2017515812A5 JP 2016565334 A JP2016565334 A JP 2016565334A JP 2016565334 A JP2016565334 A JP 2016565334A JP 2017515812 A5 JP2017515812 A5 JP 2017515812A5
Authority
JP
Japan
Prior art keywords
aluminum
pharmaceutical composition
composition according
oxyhydroxide
aluminum salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016565334A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515812A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/059341 external-priority patent/WO2015165968A1/en
Publication of JP2017515812A publication Critical patent/JP2017515812A/ja
Publication of JP2017515812A5 publication Critical patent/JP2017515812A5/ja
Pending legal-status Critical Current

Links

JP2016565334A 2014-04-29 2015-04-29 アルツハイマー病（ａｄ）の処置および予防 Pending JP2017515812A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14166355.9 2014-04-29
EP14166388.0 2014-04-29
EP14166388 2014-04-29
EP14166355 2014-04-29
PCT/EP2015/059341 WO2015165968A1 (en) 2014-04-29 2015-04-29 Treatment and prevention of alzheimer's disease (ad)

Publications (2)

Publication Number Publication Date
JP2017515812A JP2017515812A (ja) 2017-06-15
JP2017515812A5 true JP2017515812A5 (https=) 2018-05-31

Family

ID=53039897

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016565334A Pending JP2017515812A (ja) 2014-04-29 2015-04-29 アルツハイマー病（ａｄ）の処置および予防

Country Status (12)

Country Link
US (3) US11065273B2 (https=)
EP (2) EP3137094B1 (https=)
JP (1) JP2017515812A (https=)
KR (1) KR102506460B1 (https=)
CN (1) CN106659736A (https=)
AU (1) AU2015254665A1 (https=)
CA (1) CA2946931A1 (https=)
DK (1) DK3137094T3 (https=)
FI (1) FI3137094T3 (https=)
PL (1) PL3137094T3 (https=)
PT (1) PT3137094T (https=)
WO (1) WO2015165968A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102460465B1 (ko) * 2014-04-29 2022-10-27 어드밴티지 테라퓨틱스, 인코포레이티드 알츠하이머병（ａｄ）의 치료 및 예방
LT3137093T (lt) * 2014-04-29 2017-12-11 Affiris Ag Alzheimerio ligos (ad) gydymas ir prevencija
FI3137094T3 (fi) 2014-04-29 2023-03-20 Advantage Therapeutics Inc Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3440593A (en) 1993-01-14 1994-08-15 Nelson Arispe Methods and compositions for blocking amyloid protein ion channels
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
ATE514707T1 (de) * 2002-04-19 2011-07-15 Univ Toronto Immunologisches verfahren und zusammensetzungen für die behandlung der krankheit von alzheimer
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
WO2009105641A2 (en) 2008-02-20 2009-08-27 New York University Preventing and treating amyloid-beta deposition by stimulation of innate immunity
AT506819B1 (de) 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
AT506820B1 (de) 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
EP2145898A1 (en) * 2008-07-15 2010-01-20 CHIESI FARMACEUTICI S.p.A. Anti-amyloid immunogenic compositions, methods and uses
CA2793580A1 (en) * 2010-03-29 2011-10-06 Novartis Ag Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
KR102460465B1 (ko) 2014-04-29 2022-10-27 어드밴티지 테라퓨틱스, 인코포레이티드 알츠하이머병（ａｄ）의 치료 및 예방
FI3137094T3 (fi) 2014-04-29 2023-03-20 Advantage Therapeutics Inc Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen
LT3137093T (lt) 2014-04-29 2017-12-11 Affiris Ag Alzheimerio ligos (ad) gydymas ir prevencija

Similar Documents

Publication Publication Date Title
EA201492021A1 (ru) Антительный состав
JP2015527402A5 (https=)
JP2015212268A5 (https=)
SMAP200700047A (it) Forme di dosaggio di risedronato
HRP20200072T1 (hr) Načini doziranja za spojeve klase ehinokandina
JP2012508734A5 (https=)
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
JP2017515812A5 (https=)
Heathcote et al. LONG TERM (4 YEAR) EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-POSITIVE PATIENTS (HBEAG+) WITH CHRONIC HEPATITIS B (STUDY 103): PRELIMINARY ANALYSIS: 477
JP2017105859A5 (https=)
MA42301B1 (fr) Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone
JP2017514831A5 (https=)
NZ731518A (en) Formulations of a pi3k/mtor-inhibitor for intravenous administration
JP2019531286A5 (https=)
FI3137094T3 (fi) Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen
RU2016137926A (ru) Композиции грапипранта и способы их применения
JP2019515033A5 (https=)
JP2017516828A5 (https=)
SI3137093T1 (en) Treatment and prevention of Alzheimer's disease
JP2017518275A5 (https=)
JP2015521598A5 (https=)
JP2017514829A5 (https=)
JP2017513866A5 (https=)
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)